PT-141
Evidence score · 3 ref. PubMed / PMCLyophilized research compound · CAS 189691-06-3
Bremelanotide — selective MC4R/MC3R analog, in vitro study tool for the central melanocortinergic axis.
Not intended for veterinary, diagnostic or therapeutic use. No indication for in vivo use. To be handled exclusively by qualified personnel.
- CAS No.
- 189691-06-3
- Molecular weight
- 1025.18 g/mol
- Molecular formula
- C50H68N14O10
Effects documented in the literature
PT-141 (Bremelanotide) is a cyclic heptapeptide derived from Melanotan II with increased selectivity for the MC4R and MC3R receptors, and reduced affinity for MC1R (thus minimal pigmentary effect). Studies (PMID 18684229, PMC5310636) characterize activation of pro-opiomelanocortinergic neurons in the paraventricular hypothalamic nucleus, modulating central release of nitric oxide and dopamine. At the hormonal level, unlike vasoactive compounds, PT-141 acts centrally without significantly altering systemic blood pressure at pharmacological doses. The studies describe stimulation of copulatory behavior in preclinical models and an effect on satiety via the MC4R-leptin pathway. These data come from the scientific literature and are provided strictly for informational purposes in a research context. This product is not intended for veterinary, diagnostic or therapeutic use and is not recommended for any use outside a scientific, professional and research setting. [1][2][3]
Background, storage, reconstitution
- Research background
- Cyclic heptapeptide used as a pharmacological tool for MC4R signaling on hypothalamic neurons.
- Storage
- Lyophilized: −20 °C. Reconstituted: 2–8 °C.
- Reconstitution (lab)
- Sterile bacteriostatic water.→ Dilution calculator
PubMed references
- View on PubMed →[1] PubMedPMID 31599840
- View on PMC →[2] PMCPMC6819023
- View on PMC →[3] PMCPMC8788464